REVENUE (Tables)

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

The Company's revenue by segment payers/customer groups for the years ended December 31, 2023, 2022 and 2021 is as follows:

	For the Year Ended December 31, 2023								For the Year Ended December 31, 2022								For the Year Ended December 31, 2021
	North America		Europe		Other		Total		North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	24	%	—	%	—	%	24	%	22	%	—	%	—	%	22	%	21	%	—	%	—	%	21	%
Patients	9	%	—	%	—	%	9	%	8	%	—	%	—	%	8	%	7	%	—	%	—	%	7	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	36	%	—	%	—	%	36	%	39	%	—	%	—	%	39	%	42	%	—	%	—	%	42	%
Total Dx revenues by payer	77	%	—	%	—	%	77	%	77	%	—	%	—	%	77	%	78	%	—	%	—	%	78	%
BLS
Pharmaceutical, biotechnology and medical device companies	10	%	9	%	4	%	23	%	10	%	9	%	4	%	23	%	10	%	9	%	3	%	22	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%	88	%	9	%	3	%	100	%

Contract with Customer, Contract Asset, Contract Liability, and Receivable

	December 31, 2023		December 31, 2022
Dx accounts receivable	$	1,135.2	$	1,046.9
BLS accounts receivable	810.8		769.4
Less BLS allowance for doubtful accounts	(32.7)		(30.8)
Accounts receivable	$	1,913.3	$	1,785.5
Gross unbilled services	$	192.9	$	222.3
Less reserve for unbilled services	(7.5)		(10.6)
Unbilled services	$	185.4	$	211.8
Unearned revenue	$	421.7	$	310.6